Cheng C, Zhao L, Zhao Q, Moskvin V, Buchsbaum J, Das I
Indiana University- School of Medicine, Bloomington, IN.
Indiana University Health Proton Therapy Center, Bloomington, IN.
Med Phys. 2012 Jun;39(6Part14):3771. doi: 10.1118/1.4735369.
To examine the various processes involved and to assess their effects on the accuracy in proton therapy.
Proton therapy involved several processes: (1) Beam commissioning. (2) CT scan of patient. (3) Contouring. (4) Treatment planning. (5) Output factor measurements for each field. (6) Patient setup verification with image guidance. (7) Dose delivery. (8) Neutron dose and proton RBE at the distal edge. Within each step, there are several sub-processes that each may contribute to the uncertainty in the treatment. By analyzing each of the subprocesseswithin each process, based on measurements or published data, we estimated a % uncertainty to each sub-process and/or a distance uncertainty (in millimeter) on the proton range. A total uncertainty in proton therapy is estimated.
The uncertainties assessed for the various processes are : (1) ±1.5%; (4) ±3.0%, and 1-3mm; (5) ±2.0%; (6) ±2 mm; (7) ±2.0%, ±2mm. The uncertainties in (2) CT, (3) contouring and neutron dose in (8) strongly depend on the location and type of the tumor. On the other hand, the proton RBE at the distal edge in (9) is still debatable and may affect the dose uncertainty from 0-20% depending on which value we want to accept. Thus the overall uncertainty in proton therapy is at least ±4.5% and ±4 mm (by adding the various uncertainties in quadrature), without consideration of processes (2), (3) and (8), and the RBE effect.
Due to the complexity in proton therapy and the various factors that may affect the accuracy in proton therapy, it is far more complicated to assess the accuracy in proton therapy. Our preliminary study showed that the accuracy in proton therapy is at least ± 4.5% in dose delivered to a tumor with an uncertainty of ±4mm to the distal edge of the SOBP.
研究质子治疗中涉及的各种过程,并评估它们对质子治疗准确性的影响。
质子治疗涉及多个过程:(1)束流调试。(2)患者CT扫描。(3)轮廓勾画。(4)治疗计划。(5)每个射野的输出因子测量。(6)利用图像引导进行患者摆位验证。(7)剂量输送。(8)远端边缘处的中子剂量和质子相对生物效应(RBE)。在每个步骤中,都有几个子过程,每个子过程都可能导致治疗中的不确定性。通过基于测量或已发表数据分析每个过程中的每个子过程,我们估计了每个子过程的百分比不确定性和/或质子射程上的距离不确定性(以毫米为单位)。估计了质子治疗中的总不确定性。
评估的各个过程的不确定性为:(1)±1.5%;(4)±3.0%,以及1 - 3毫米;(5)±2.0%;(6)±2毫米;(7)±2.0%,±2毫米。(2)CT、(3)轮廓勾画以及(8)中的中子剂量的不确定性很大程度上取决于肿瘤的位置和类型。另一方面,(9)中远端边缘处的质子RBE仍存在争议,根据我们所接受的值,可能会使剂量不确定性在0 - 20%之间变化。因此,不考虑过程(2)、(3)、(8)以及RBE效应,质子治疗中的总体不确定性至少为±4.5%和±4毫米(通过将各种不确定性进行平方和相加)。
由于质子治疗的复杂性以及可能影响质子治疗准确性的各种因素,评估质子治疗的准确性要复杂得多。我们的初步研究表明,对于输送到肿瘤的剂量,质子治疗的准确性至少为±4.5%,对布拉格峰远端边缘处的不确定性为±4毫米。